Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Pharmacol Exp Ther. 2014 Jul 30;351(1):96–104. doi: 10.1124/jpet.114.217034

Fig. 4.

Fig. 4

AnxA1 mobilization within human PMN and underlying mechanisms. (A) AnxA1 expression in cytosolic (Cyt), membrane (Mem), or supernatant (Sup) fractions from human PMN upon NaHS (10–100 μM, 30 minutes) challenge. Optical density is expressed as the percentage of total AnxA1. (B) AnxA1 expression in cytosolic and membrane fractions from human PMN upon treatment with PDE4 inhibitor rolipram (1–100 μM, 30 minutes). Statistical analysis was made using one-way analysis of variance (*P < 0.05, **P < 0.01 versus vehicle; n = 4).